AB
ABVC.US ABVC Biopharma Inc
- Market cap
- USD 26.2M
- P/E
- -
- P/B
- 2.54x
- ROE
- -11.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABVC.US undervalued?
Graham numberThe Graham number of ABVC Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABVC Biopharma Inc fundamental analysis
No fundamental analysis for ABVC Biopharma Inc yet.
ABVC Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, wh…
Full company profileABVC Biopharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ABVC Biopharma Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.00 | 3.20K | 6.96K | 702K | 483K | 356K | 970K | 152K | 510K | 796K | - |
| Gross Profit | -32.00 | 947.00 | -222K | 682K | 464K | 351K | 683K | -150K | 509K | 796K | - |
| Operating Income | -11.0M | -4.14M | -2.78M | -3.46M | -8.51M | -11.7M | -15.1M | -6.77M | -4.71M | -7.15M | -4.79M |
| EBITDA | -11.0M | -4.09M | -5.92M | -3.47M | -10.4M | -11.0M | -15.2M | -6.33M | -4.34M | -7.43M | -4.65M |
| Net Income | -11.0M | -4.24M | -5.58M | -3.64M | -9.79M | -12.8M | -16.4M | -7.79M | -4.90M | -7.91M | -1.53M |
| EPS | -9.40 | -3.58 | -4.69 | -2.08 | -4.97 | -5.12 | -5.19 | -1.80 | -0.42 | -0.34 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 18.6K | 6.60M | 96.3K | 6.93M | 14.8M | 13.7M | 10.9M | 7.78M | 7.54M | 21.1M | 20.3M |
| Total Liabilities | 6.54M | 4.14M | 5.85M | 7.05M | 8.94M | 4.83M | 6.34M | 6.53M | 6.82M | 7.76M | 8.55M |
| Shareholders' Equity | -6.52M | 1.65M | -5.75M | -151K | 6.60M | 8.84M | 4.45M | 1.55M | 1.23M | 11.1M | 13.1M |
| Cash & Short-term Investments | 18.6K | 257K | 40.0K | 144K | 5.00M | 5.94M | 1.47M | 796K | 929K | 746K | 66.5K |
| Total Debt | - | 1.23M | 800K | 4.58M | 6.77M | 3.34M | 3.41M | 2.77M | 3.20M | 3.47M | 2.51M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.47M | -1.68M | -630K | -3.13M | -4.56M | -7.60M | -7.40M | -4.19M | -1.81M | -2.99M | -2.10M |
| Capital Expenditure | 0.00 | 0.00 | 17.5K | 17.5K | 17.5K | 17.5K | 120K | 21.2K | 5.00 | 5.79K | 652K |
| Free Cash Flow | -3.47M | -1.68M | -630K | -3.13M | -4.56M | -7.62M | -7.52M | -4.21M | -1.81M | -2.99M | -2.43M |
| Ratios | |||||||||||
| ROE | - | -256.6% | - | - | -148.4% | -145.2% | -368.8% | -501.1% | -399.9% | -71.2% | -11.7% |
| ROA | -59,038.6% | -64.2% | -5,791.2% | -52.6% | -66.3% | -93.7% | -150.2% | -100.0% | -65.0% | -37.5% | -7.5% |
| Net Profit Margin | -34,399,184.4% | -132,755.3% | -80,152.1% | -519.0% | -2,027.0% | -3,608.5% | -1,693.5% | -5,109.3% | -962.1% | -993.6% | - |
| Debt to Equity | - | 0.74x | - | - | 1.03x | 0.38x | 0.77x | 1.78x | 2.61x | 0.31x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ABVC Biopharma Inc dividends
ABVC Biopharma Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jul 25, 2023.
Who owns ABVC Biopharma Inc
- Insiders 17.90%
- Institutions 4.50%
- Public & others 77.61%
- Shares outstanding 27.0M
- Free float 22.0M
Top funds holding ABVC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 361K | 1.35% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 108K | 0.41% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 35.5K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 31.1K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 14.8K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding ABVC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 374K | 1.40% | +96.51% | Jun 2026 |
| Geode Capital Management, LLC | 228K | 0.85% | +3.11% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 97.4K | 0.36% | 0.00% | Jun 2026 |
| State Street Corp | 72.8K | 0.27% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 72.1K | 0.27% | 0.00% | Jun 2026 |
| BlackRock Inc | 56.4K | 0.21% | 0.00% | Jun 2026 |
| Northern Trust Corp | 48.6K | 0.18% | +51.60% | Jun 2026 |
| XTX Topco Ltd | 48.3K | 0.18% | 0.00% | Jun 2026 |
| Panagora Asset Management Inc | 36.7K | 0.14% | 0.00% | Jun 2026 |
| UBS Group AG | 34.1K | 0.13% | +1,826.76% | Jun 2026 |
| Jane Street Group LLC | 20.1K | 0.08% | 0.00% | Jun 2026 |
| Citigroup Inc | 540.00 | 0.00% | 0.00% | Jun 2026 |
| LifeSteps Financial, Inc. | 300.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 17.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Squarepoint Ops LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
ABVC Biopharma Inc company profile
- Company name
- ABVC Biopharma Inc
- Ticker
- ABVC.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
- Phone
- 510 668 0881
- Website
- abvcpharma.com
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
ABVC Biopharma Inc management
3- Mr. Eugene JiangChairman & Chief Business Officer · born 1986
- Dr. Uttam Yashwant Patil Ph.D.CEO & Interim CFO · born 1986
- Dr. Tsung-Shann Jiang EMBA, Ph.D.Chief Scientific Officer, Chief Strategy Officer & Director · born 1954